A novel orexin‑targeting pill may treat ADHD effectively while avoiding cardiovascular side effects.
The pharmaceutical landscape for attention-deficit hyperactivity disorder may be on the cusp of change. Alkermes has disclosed early clinical data for ALKS 7290 an experimental compound that activates the brain’s orexin system. In a brief, two-week study involving fifty adult participants, the highest dose of the drug shifted patients from a severe rating of ADHD to a mild one, with measurable gains in both attention and activity control.
What makes the findings stand out is the absence of any alarming cardiovascular signals. Researchers reported stable heart-rate, blood-pressure, and electrocardiogram readings throughout the trial, a contrast to the well-documented tachycardia and hypertension risk linked to conventional stimulants such as Ritalin and Adderall.
Trial outcomes and safety observations
Participants were randomized to receive either ALKS 7290 or a placebo tablet each day for fourteen days. Those on the drug displayed a marked reduction in the core ADHD metrics used by clinicians. Inattention scores dropped by roughly 40 % at the high dose, while hyperactivity indices fell by a comparable margin.
Importantly, the improvement was observed across the entire cohort, not just a subset of responders.
The safety record was equally encouraging. No serious adverse events were recorded. The most frequently reported mild issues were dizziness, transient insomnia, occasional constipation, and a modest increase in urinary frequency. Cardiovascular parameters remained within normal limits and no participant experienced the anxiety or insomnia often attributed to stimulant therapy.
Why orexin agonism differs from traditional stimulants
Conventional ADHD medications boost dopamine and noradrenaline levels, enhancing motivation and alertness but also triggering the body’s fight-or-flight cascade. This physiologic activation can raise pulse and pressure, and in susceptible individuals may precipitate psychotic symptoms. Dr. Michael Halassa of Virginia Tech’s Fralin Biomedical Research Institute explains that orexin neurons sit upstream of those pathways, governing wakefulness and general arousal without directly flooding the brain with catecholamines.
In practice, an orexin agonist like ALKS 7290 appears to keep the brain “on-task” by stabilising the wakefulness circuitry. Dr. Halassa notes, “Essentially, it does what stimulants do but without the abuse potential.” The mechanism therefore promises non-stimulant efficacy—a long-sought after goal for clinicians who encounter patients unable to tolerate standard therapies.
Expert commentary and the road ahead
Both Dr. Halassa and Dr. Barbara Sahakian of the University of Cambridge highlighted the clinical relevance of a non-stimulant that matches stimulant potency. Dr. Sahakian remarked, “Many individuals with ADHD either do not respond to stimulants or suffer intolerable side effects; a well-tolerated alternative would be a major advance.” Both experts also cautioned that the current data derive from a small sample and that larger, multi-center trials are needed to confirm durability and generalisability.
A second-phase study enrolling more than 300 participants is already under way. If those results echo the initial findings, regulators could consider approval within the next five years—a timeline Dr. Halassa likens to the trajectory of Ozempic which expanded from a diabetes treatment to a household name for weight management and beyond.
Should the larger trial succeed, the drug could reshape prescribing patterns for ADHD, offering clinicians a third therapeutic class alongside stimulants and the limited existing non-stimulant options such as atomoxetine. For patients, the prospect of improved focus without the worry of heart-rate spikes or addiction risk could change daily living for millions worldwide.
